Boxed warning on anti-smoking drugs

The FDA has added a boxed warning on buproprion (wellbutrin and zyban) and varenicline (chantix) for the risk of neuropsychiatric symptoms (agitation, hostility, depression, and suicidality), which warrants cessation of the drugs. However, distinguishing these symptoms from nicotine withdrawal can be challenging (FDA site).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment